Medication info
Suga Tablet 10 mg (Dapagliflozin Monohydrate Mixed Powder)

Suga Tablet 10 mg (Dapagliflozin Monohydrate Mixed Powder)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›Strength being verified
Manufacturer / importer
Unimed Pharmaceuticals Co., Ltd.
Appearance
Yellow, biconvex, diamond-shaped film-coated tablet
Packaging
28 tablets/box (14 tablets/PTP × 2, 7 tablets/PTP × 4), 30 tablets/bottle
Approval status
Active

MFDS item code 202103301 · Approved 2021.04.22 · Insurance code 649508140

Summary

Main use
Treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior history of antidiabetic drug treatment, the recommended initial dose of this medicine when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dosage adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Unimed Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular diseases
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • estimated glomerular filtration rate reduction
  • end-stage renal disease
View approved original text

This medication is used alongside diet and exercise to help control blood sugar in patients with type 2 diabetes and is also applicable to patients at risk of cardiovascular diseases. It helps reduce cardiovascular mortality and hospitalization risks in patients with chronic heart failure and is administered in conjunction with standard heart failure treatments. For patients with chronic kidney disease, it is used alongside other renal disease treatments to lower the risk of renal function decline and related mortality. In summary, this medication is effectively used for treating type 2 diabetes, chronic heart failure, and chronic kidney disease.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior history of antidiabetic drug treatment, the recommended initial dose of this medicine when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dosage adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used in certain patients. Patients who are allergic to this medication's active ingredient or additives, patients with type 1 diabetes, patients with diabetic ketoacidosis, and patients with lactose intolerance should not take this medication. Also, patients undergoing dialysis should not use this medication. Patients with reduced fluid volume or renal dysfunction should use this medication cautiously. This medication may lower blood pressure or cause temporary changes in renal function; therefore, fluid status and renal function must be checked prior to administration, and caution should be taken to observe for symptoms of hypotension and renal function during use. Especially in patients with moderate to severe renal impairment, blood sugar control efficacy may be diminished. This medication contains colorants Yellow No. 4 and Yellow No. 5, so patients with allergies to these components should use it carefully. Various side effects may occur during treatment with this medication. The most common side effect is genital infections, which may occur more frequently in females. Other reported side effects include hypoglycemia, fluid volume reduction, dizziness, constipation, dry mouth, and urinary tract infections. This medication can affect renal function and may temporarily increase serum creatinine levels in some patients. Such changes may occur more frequently in patients with chronic kidney disease or in older adults, so caution is necessary. Rarely, serious infections like necrotizing fasciitis may occur, so if pain, swelling, or redness around the genital area appears, immediate consultation with healthcare professionals is necessary. This medication is not recommended for pregnant women, and administration should be discontinued immediately upon confirmation of pregnancy. Additionally, breastfeeding women should not use this medication. When used in conjunction with hypoglycemic agents such as insulin or sulfonylureas, there may be an increased risk of hypoglycemia; therefore, dose adjustment may be necessary when using these drugs together. There is no specific antidote for overdose; therefore, it is crucial to receive symptomatic treatment. Finally, this medication has not been established for safety and efficacy in children, so its use should be avoided. Close observation of hypoglycemia symptoms and fluid volume changes is important during treatment with this medication, and immediate consultation with a physician is necessary if any abnormal symptoms occur.

Side effects

vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, lumbar pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, elevated hematocrit, decreased renal creatinine clearance early in treatment, dyslipidemia, increased serum creatinine early in treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, chest pain, dyspepsia, nausea, diarrhea, vomiting, urinary retention, increased alanine aminotransferase, increased aspartate aminotransferase, decreased appetite, somnolence, headache, sensory loss, nasopharyngitis, upper respiratory infection, chest discomfort, peripheral edema, generalized edema, hunger, vaginal discharge, menstrual irregularities, itching, urticaria, sweating, arthralgia, musculoskeletal pain, limb pain, muscular weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it must be stored in a tightly closed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication safely.

Appearance and packaging

Appearance

Yellow, biconvex, diamond-shaped film-coated tablet

Package unit

28 tablets/box (14 tablets/PTP × 2, 7 tablets/PTP × 4), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.